Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the efficacy and safety of vildagliptin 50mg qd
as add-on therapy to sulfonylurea in patients with type 2 diabetes inadequately controlled
with prior sulfonylurea monotherapy as compared to placebo. This study is aimed at supporting
the regulatory approval in China of vildagliptin as combination therapy with sulfonylureas in
the treatment of type 2 diabetes.